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Background
The mechanisms underlying Burkitt’s Lymphoma (BL)
chemoresistance and how it can be circumvented remain
undetermined.The histone deacetylase inhibitors (HDACi)
represent a novel class of agents which have demonstrated
potent antitumor activity in preclinical models and pro-
mising clinical efficacy in cancer patients. The aim of this
study was to evaluate the cell death enhancement effect of
Sodium Butyrate (NaB), a HDACi combined with subopti-
mal concentration of etoposide (VP-16) and identify genes
differentially regulated by this combination to provide
rationale for novel drug combination patterns.
Materials and methods
Raji BL cell line was treated with NaB isolated or com-
bined with VP-16. Growth inhibition and cell cycle were
analyzed in response to treatment using trypan blue exclu-
sion assay and flow cytometry. Gene expression profiles
were determined using One-Color Microarray-Based Gene
Expression (Agilent Technologies) and analyzed on
Feature Extraction v 9.5.1 software.
Results
NaB/VP-16 combined treatment decreased cell prolifera-
tion and survival, and blocked cell cycle progression at
G2/M with a concurrent decrease in S phase in Raji cells
at 24h. Microarray profile showed upregulation of genes
related to apoptosis, cell cycle arrest and response to
DNA breaks. We also observed downregulation of genes
related to cell cycle progression and angiogenesis.
Conclusions
Alterations in critical genes involved in cell survival,
angiogenesis, cell cycle and DNA damage response were
identified. Pathways identified may represent potential
targets for combined therapy protocols which have been
emerging to improve treatment strategies to circumvent
responseless BL patients.
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